The principle route by which organisms obtain bulk quantities of amino acids is through the transport of di-and tri-peptides across cellular membranes. This process is mediated through a large and diverse family of integral membrane proteins called the proton dependent oligopeptide transporter (POT) family, also referred to simply as the peptide transporter or PTR2 family [1] . POT family transporters are found in all organisms, with the notable exception of the archaea, and use the proton electrochemical gradient to drive the uptake of di-and tri-peptides across cell membranes. The human genome contains four members of the POT family, which belong to the SLC15A1-A4 gene family and are called PepT1, PepT2, PHT2 and PHT1. The PepT1 gene was first identified in 1994, and was quickly established as the principle route through which peptides are absorbed across the enterocyte brush border membrane in the small intestine [2] . The closely related PepT2 protein was later identified in kidney cells, and is commonly referred to as the renal peptide transporter, although the tissue distribution of PepT2 is significantly broader, with confirmed reports of expression in the liver, lung, testis, and central nervous system [3] . The physiological role of PepT2 in these diverse organs is however still unclear. Early work on peptide transporter physiology discovered that peptide transporters were primarily responsible for the oral bioavailability of many commonly prescribed drug molecules, most notably the beta-lactam antibiotics and certain angiotensin converting enzyme inhibitors. This additional function was ascribed to the similar stereochemical properties these drug molecules have to naturally occurring peptides, with main consensus being that these drugs were simply 'carried along for the ride'. This realisation led to the development of specifically engineered peptide pro-drugs; molecules that can be attached to peptide scaffolds and subsequently utilise the widespread tissue distribution of peptide transporters to improve their pharmacokinetic properties, most notably oral bioavailability. There are currently a number of peptide pro-drugs being routinely prescribed to patients, such as the antiviral valacyclovir and the vasopressor midrodrine, all of which take advantage of endogenous peptide transporters to improve both efficacy and bioavailability over the original parent molecule [4] .
into the molecular mechanism of transport we determined the crystal structure of a prokaryotic member of the POT family, from the bacterium Shewanella oneidensis, PepT So [5] . PepT So shows a high degree of sequence conservation within the transmembrane region (~30 % identity) to the mammalian PepT1 and PepT2 proteins and associated functional data reveal similar kinetic properties supporting a common mechanism of peptide transport. PepT So contains 14 transmembrane helices, of which helices H1-H12 adopt the overall fold observed previously in other members of the MFS transporter superfamily, with the N-and C-terminal six helical bundles, formed by helices H1-H6 and H7-H12, coming together to form a V-shaped transporter, with both halves related by a pseudo-two fold symmetry axis running normal to the membrane plane. PepT So is the largest member of the MFS family for which a crystal structure is available, with the additional two helices being formed from the large intracellular loop connecting the end of helix H6 to the start of helix H7. This raises interesting questions as to the role these additional helices in the biochemistry of bacterial peptide transporters and more generally within the MFS.
The structure revealed a previously unobserved ligand bound occluded state, with an unidentified ligand bound within a large central cavity that is closed to both side of the membrane. Many of the residues conserved between PepT So and the mammalian peptide transporters cluster around this cavity.
The cavity is striking for the number and placement of charged residues that cluster to opposite ends to create a potential macro dipole across the two halves of the transporter. This orientation of charged residues within the binding site suggests a possible mechanism of peptide recognition, with the amino terminus of peptides interacting with the conserved negative glutamic acid on the C-terminal six helical bundle and the carboxy termini interacting with the conserved cluster of positively charged arginines and lysine residues on the opposing, N-terminal bundle. The additional placement of three conserved tyrosine residues is also reminiscent of many antigen recognistion sites, where tyrosines play pivotal roles in providing a flexible, hydrophobic environment for side chain accommodation.
These characteristics could also explain the specificity we observe within the POT family for di-and tri-peptides, as the dimensions of the cavity are only sufficient to accommodate peptides of these lengths, with larger tetra-peptides being sterically restricted and single amino acids unable to interact with both halves of the transporter and so presumably fail to trigger the required conformation changes to re-orientate the binding site across the membrane.
The occluded conformation reveals many intriguing new features concerning possible mechanisms for transport, both generally within the MFS superfamily and more specifically within the POT peptide transporters. The most obvious of which is the potential significance of the extracellular cavity we observe opening out towards the extracellular side of the membrane. The cavity causes PepT So to adopt an overall asymmetric state, breaking the pseudo two-fold symmetry observed in previous MFS structures. We are currently working to determine the significance of this with respect to specific th EITG Conference Session 4: Peptide transport conformational changes within the C-terminal helical bundle during transport. The structure however does suggest that within the POT family at least, it is the C-terminal six helical bundle that may contain the mobile gates, both extracellular and intracellular, that alternately open and close around peptides to move them across the membrane. Interestingly, observed at the base of the extracellular cavity is a conserved histidine residue, shown to be protonated during the transport cycle in PepT1.
Mutating this residue in PepT So also abolishes transport; raising the question as to what role both this residue and the additional cavity play in the mechanism of peptide transport.
There is a pressing requirement to understand the molecular mechanism of the human peptide 
Conclusion.
Increases with pH sodium-dependent component of the stimulating effect of easily hydrolysable dipeptides is due to the membrane digestion, and possibly due to the operation of the enzymatic transport ensemble, as the SCC responses to the dipeptides are more than SCC responses on a mixture of amino acids, of which they consist. Sodium independent transport component of dipeptides decreasing with pH apparently caused by functioning in the apical membrane of enterocytes of proton-dependent transporter PepT1.
